Date: 2014-07-24
Type of information: Grant
Company: 4SC (Germany) Crelux (Germany)
Investors: m4 - Personalised Medicine and Targeted Therapies\' programme of the German Federal Ministry of Research and Education (BMBF) (Germany)
Amount: undisclosed
Funding type: grant
Planned used: The research grant has been awarded for the discovery and identification of new epigenetic anti-cancer compounds. A joint research project between 4SC Discovery and CRELUX initially running for eleven months will receive funding under the Munich m4 biotech cluster programme. It will focus on the identification of bromodomain inhibitors and their possible later use in personalised medicine. Bromodomains are considered promising targets for new drugs. By specifically blocking these bromodomains, it is intended to influence tumour cells in such a way that they are either identified and destroyed by the body\'s immune system or driven into apoptosis (programmed cell death). Bromodomains allow epigenetic enzymes to attach to DNA complexes thus regulating the reading of the genetic information (DNA) in the cells. If these processes malfunction, the development of diseases such as cancer may be facilitated. An objective of the funded m4 project by CRELUX and 4SC Discovery is the modulation of these mechanisms with new small-molecule compounds.
Others: * On July 24, 2014, 4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, announced that its subsidiary 4SC Discovery GmbH, which specialises in the discovery and early-stage research of new substances, has been awarded a research grant for the discovery and identification of new epigenetic anti-cancer compounds in collaboration with its strategic cooperation partner CRELUX GmbH.
Therapeutic area: Cancer - Oncology
